Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1

References

• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Budman DR, Berry DA, Cirrincione CT, . Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205–11.
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Roche H, Kerbrat P, . Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 2006;17:85–92.
   PubMed Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD, . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–83.
   PubMed Web of Science ®Google Scholar
• Focan C, Andrien JM, Closon MT, . Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 1993;11:1253–63.
   PubMed Web of Science ®Google Scholar
• Brufman G, Colajori E, Ghilezan N, . Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. Ann Oncol 1997;8:155–62.
   PubMedGoogle Scholar
• Bonneterre J, Roche H, Kerbrat P, . Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005;23:2686–93.
   PubMed Web of Science ®Google Scholar
• Baker SD, Verweij J, Rowinsky EK, . Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. J Natl Cancer Inst 2002;94:1883–8.
   PubMed Web of Science ®Google Scholar
• Gurney H. Developing a new framework for dose calculation. J Clin Oncol 2006;24:1489–90.
   PubMed Web of Science ®Google Scholar
• Gurney HP, Ackland S, Gebski V, Farrell G. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation. J Clin Oncol 1998;16:2299–304.
   PubMed Web of Science ®Google Scholar
• Jakobsen P, Bastholt L, Dalmark M, . A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 1991;28:465–9.
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Freijs A, Larsson R, . Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996;14:1581–8.
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 2006;58:143–56.
   PubMed Web of Science ®Google Scholar
• Meinardi MT, Van Der Graaf WT, Gietema JA, . Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques. Heart 2002;88:81–2.
   PubMedGoogle Scholar
• Praga C, Bergh J, Bliss J, . Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:4179–91.
   PubMed Web of Science ®Google Scholar
• Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003;89:1837–42.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Price K, Castiglione-Gertsch M, . Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 1998;34:1693–700.
   PubMed Web of Science ®Google Scholar
• Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246–57.
   PubMed Web of Science ®Google Scholar
• Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999;80:1763–6.
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997;75:301–5.
   PubMed Web of Science ®Google Scholar
• Bergh J, Wiklund T, Erikstein B, . Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000;356:1384–91.
   PubMed Web of Science ®Google Scholar
• Wilking N, Lidbrink E, Wiklund T, . Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 2007;18:694–700.
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Paesmans M, Beauduin M, . Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicenter study. J Clin Oncol 2009;27:720–5.
   PubMedGoogle Scholar
• Margolin S, Bengtsson NO, Carlsson L, . A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/ tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncol 2011;50:35–41.
   PubMed Web of Science ®Google Scholar
• Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19:602–11.
   PubMed Web of Science ®Google Scholar